CellRapeutics™ IGHV4-34 BCR-targeted CAR Engineering Service for Precision Targeting to Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma (DLBCL) remains one of the most aggressive and common forms of non-Hodgkin lymphoma. Despite advances in immunotherapy, particularly with Chimeric Antigen Receptor T-cell (CAR-T) therapies, the durability of responses remains variable. With our years of experience in CART field, Creative Biolabs is committed to delivering refined precision-targeting immunotherapies, specifically by harnessing the immunoglobulin heavy variable gene 4-34 (IGHV4-34) B Cell Receptor (BCR).

IGHV4-34 BCR and Its Potential for Disease Treatment

IGHV4-34 is a distinctive immunoglobulin heavy chain variable region gene often expressed in a significant subset of B cell malignancies. Notably, up to 30% of activated B cell (ABC) DLBCL, approximately 35% of primary central nervous system lymphomas, 65% of vitreoretinal lymphomas, and around 35% of hairy cell leukemia variants express IGHV4-34. These statistics underscore the critical role of IGHV4-34 in tumorigenesis via delivering survival and proliferative signals to malignant B cells.

Importantly, IGHV4-34+ B cells constitute a minor fraction (~5%) of the normal B cell repertoire, which makes them an attractive target for selective therapy. Leveraging this specificity, targeted CAR-T therapies against IGHV4-34 can achieve robust antitumor activity while sparing the majority of the healthy B cell population, thus reducing the risk of immunosuppression and associated complications.

IGHV4-34 BCR-Targeted CAR Engineering Strategies for Diffuse Large B Cell Lymphoma

Creative Biolabs offers a range of CAR targets and engineering strategies for B cell lymphoma, such as CD19, CD20, and CD22, we also have launched a comprehensive range of CART-related products and services to facilitate customers' CART development. To deliver more efficient and safe CAR engineering strategies, we are committed to developing an IGHV4-34 BCR-targeted CAR engineering strategy for diffuse large B cell lymphoma study and treatment. Meanwhile, we offer the one-stop CART development solution for precise performance, including initial CAR-T constructs design, in vitro and in vivo validation assays, professional project design, and project suggestions by the technical team.

Features of IGHV4-34 BCR-Targeted CAR-T Cells

What We can Offer

Creative Biolabs has pioneered the next generation of CAR-T therapies by focusing on IGHV4-34 BCR-targeted engineering, establishing a benchmark for precision targeting in B cell malignancies. Our approach integrates rigorous scientific research with tailored engineering strategies to enhance therapeutic performance.

IGHV4-34 BCR-targeted CAR engineering strategy represents a significant advancement in the treatment strategy for DLBCL and other B cell malignancies. Creative Biolabs continues to lead the field with our innovative approaches, promising better services for global customers. We continue to be committed to CART-related research and development, please feel free to contact us for relevant information.

Fundamental Benefis

• Precision Target Validation: We offer customizable biomarker assessment services to rigorously validate IGHV4-34 expression and quantify normal B-cell sparing potential across your specific patient population or cell line model, ensuring your therapeutic focus is biologically sound.
• Modular CAR Construct Design: Choose from a full spectrum of co-stimulatory domains and optimized linker designs to tailor the CAR signal intensity and T-cell persistence profile, guaranteeing a construct optimized for your desired clinical outcome.
• Vector System Flexibility: We provide expertise in multiple gene delivery platforms, including Lentivirus, Retrovirus, and mRNA-LNP systems, allowing you to select the delivery mechanism that best fits your regulatory and manufacturing strategy.

FAQ

Related Services

Why Choose Us

Creative Biolabs' CellRapeutics™ IGHV4-34 BCR-targeted CAR Engineering Strategy represents the evolution of immuno-oncology - moving from broad-spectrum elimination to highly selective precision. Our 20 years of expertise and proprietary platforms ensure that your project benefits from enhanced specificity, reduced toxicity risks, and a stronger defense against antigen escape, positioning your therapeutic candidate for success against aggressive B-cell lymphomas.

Contact our team for more information and to discuss your project. Our dedicated team of cell therapy specialists is ready to provide tailored scientific consultation.